These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9551171)

  • 1. [The difluoroquinolone lomefloxacin--an broad spectrum antimicrobial drug].
    Padeĭskaia EN; Iakovlev VP
    Antibiot Khimioter; 1998; 43(2):30-9. PubMed ID: 9551171
    [No Abstract]   [Full Text] [Related]  

  • 2. Lomefloxacin, a new difluoroquinolone: in vitro activity against gram-positive and gram-negative bacteria.
    Hoban D; Grabowski M; Koss J; Weselowski V
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):77S-82S. PubMed ID: 2791502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro evaluation of lomefloxacin].
    Dette GA; Knothe H
    Arzneimittelforschung; 1989 Aug; 39(8):832-5. PubMed ID: 2818672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro assessment of the postantibiotic effect of lomefloxacin against gram-positive and gram-negative pathogens.
    Debbia EA; Pesce A; Schito GC
    Am J Med; 1992 Apr; 92(4A):45S-47S. PubMed ID: 1316070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antimicrobial activity of sparfloxacin, a new quinolone.
    Paradelis AG; Delidou K; Grigoriadou A; Salpigides G; Pangalis A
    Drugs; 1995; 49 Suppl 2():238-9. PubMed ID: 8549316
    [No Abstract]   [Full Text] [Related]  

  • 6. Fluoroquinolone (Lomefloxacin) International Surveillance Trial: a report of 30 months of monitoring in vitro activity.
    Jones RN
    Am J Med; 1992 Apr; 92(4A):52S-57S. PubMed ID: 1316072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones.
    Prats G; Roig C; Miró E; Navarro F; Mirelis B
    Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):328-34. PubMed ID: 12072950
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria.
    Moros M; Coll R; Esteve M; Parés J; Xicota MA
    Chemioterapia; 1987 Jun; 6(2 Suppl):149-51. PubMed ID: 3509373
    [No Abstract]   [Full Text] [Related]  

  • 9. Antimicrobial activity of E-4441, a representative azetidine quinolone.
    Esteve M; Moros M; Coll R; Xicota MA; Llovera S
    Drugs Exp Clin Res; 1990; 16(9):445-9. PubMed ID: 2100245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity, pharmacokinetics and clinical studies of balofloxacin (Q-35) in obstetrics and gynaecology.
    Cho N; Miyakawa Z; Kimura T; Shimizu A; Notake Y; Kunii K
    Drugs; 1995; 49 Suppl 2():391-2. PubMed ID: 8549373
    [No Abstract]   [Full Text] [Related]  

  • 11. In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.
    Marshall SA; Jones RN; Murray PR; Washington JA; Allen SD; Gerlach EH; Erwin ME
    J Antimicrob Chemother; 1993 Dec; 32(6):877-84. PubMed ID: 8144428
    [No Abstract]   [Full Text] [Related]  

  • 12. Preliminary results on the antibacterial and killing activity of lomefloxacin.
    Stefani S; Pellegrino MB; Mezzatesta M; Speciale AM; Caccamo F; Russo G; Nicoletti G
    J Chemother; 1989 Jul; 1(4 Suppl):170-2. PubMed ID: 16312355
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of the antibacterial activity of lomefloxacin with that of other antibiotic/chemotherapeutic agents.
    Cuffini AM; Tullio V; Vaiani G; Carlone NA
    J Chemother; 1989 Jul; 1(4 Suppl):178-81. PubMed ID: 16312358
    [No Abstract]   [Full Text] [Related]  

  • 14. Postantibiotic effects of E-4868 and OPC-17116.
    Sanford MD; Jones RN
    J Antimicrob Chemother; 1993 Dec; 32(6):916-7. PubMed ID: 8144440
    [No Abstract]   [Full Text] [Related]  

  • 15. [Lomefloxacin hydrochloride (Maxaquin), a long-acting fluoroquinolone (information for specialists)].
    Kuznetsovoĭ SM
    Antibiot Khimioter; 1998; 43(2):40-1. PubMed ID: 9551172
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
    Montanari MP; Mingoia M; Varaldo PE
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3616-22. PubMed ID: 11709353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect.
    Boswell FJ; Andrews JM; Wise R
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1377-9. PubMed ID: 9174203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacodynamic and pharmacokinetic approaches to optimization of lomefloxacin].
    Iakovlev SV
    Antibiot Khimioter; 1998; 43(10):42-5. PubMed ID: 9825110
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacodynamics of quinolones.
    Dalhoff A
    Drugs; 1995; 49 Suppl 2():197-9. PubMed ID: 8549302
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro antimicrobial activity and postantibiotic effect of lomefloxacin, a new difluoroquinolone.
    Molinari G; Bandelloni R; Paglia P; Debbia E; Schito GC
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):53S-56S. PubMed ID: 2791499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.